TLR7 agonist 29 selectively targets Toll-like receptor 7 (TLR7) with an EC50 of 5.2 nM in human cells and 48.2 nM in mouse cells. This compound effectively activates bone marrow-derived macrophages, enhances myeloid cell activity within the tumor microenvironment, and upregulates the expression of key immune markers such as PD-L1, CD86, and IFN-α. TLR7 agonist 29 can also be utilized as a payload in the synthesis of antibody-drug conjugates (ADCs) for targeted cancer therapies.
TLR7 agonist 29 selectively targets Toll-like receptor 7 (TLR7) with an EC50 of 5.2 nM in human cells and 48.2 nM in mouse cells. This compound effectively activates bone marrow-derived macrophages, enhances myeloid cell activity within the tumor microenvironment, and upregulates the expression of key immune markers such as PD-L1, CD86, and IFN-α. TLR7 agonist 29 can also be utilized as a payload in the synthesis of antibody-drug conjugates (ADCs) for targeted cancer therapies.
This calculator helps you calculate mass of compound based on solution concentration, volume and molecular weight in a specific solution using the formula:
